Entrada Therapeutics (TRDA) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic pipeline progress and expansion

• Advancing four clinical-stage programs in Duchenne muscular dystrophy (DMD) with data readouts expected in Q2 and Q4 2026 for ENTR-601-44, and mid-2026 for ENTR-601-45.

• Expansion into ocular diseases with the nomination of ENTR-801 for Usher syndrome type 2A and plans for a second candidate in 2026.

• Partnership with Vertex on myotonic dystrophy type 1 (DM1) progressing, with global Phase 1/2 study enrollment and dosing to complete mid-2026.

• Pipeline includes ongoing discovery in neuromuscular, ocular, and undisclosed disease areas.

• Financial runway extends into Q3 2027, supporting continued R&D and expansion.

Clinical and scientific differentiation

• EEV platform enables 25-fold improvement in endosomal escape, leading to higher muscle concentrations at lower doses compared to antibody-based therapies.

• Optimized PMO sequences and satellite cell uptake are expected to drive functional benefit and safety.

• Healthy volunteer studies showed zero treatment-related adverse events and strong target engagement.

• Lower drug load reduces risk of antibody response and manufacturing burden.

• Data from ENTR-601-44 expected to de-risk subsequent DMD programs due to shared EEV technology.

Regulatory and commercialization strategy

• Ex-U.S. clinical strategy accelerates data collection and supports U.S. FDA accelerated approval pathway.

• ELEVATE 44-201 study designed to support U.S. accelerated approval and global registration.

• Targeting over 14,000 DMD patients in the U.S. and Europe with multiple exon-skipping therapies.

• Ocular program aims for clinically relevant exon skipping and favorable dosing intervals.

• Ongoing efforts to expand into metabolic, CNS, and other undisclosed indications.